

PATIENT SAFETY CARD

+ Important Safety Information for Patients Taking **ULTOMIRIS** (ravulizumab-cwvz) or **SOLIRIS** (eculizumab)

ULTOMIRIS® and SOLIRIS® can increase your chance of getting **serious meningococcal infections. These infections may quickly become life-threatening or cause death if not recognized and treated early.** If you experience any of the following signs and symptoms of serious meningococcal infection, you should immediately call your healthcare provider or seek emergency medical care, preferably in a major emergency medical care center:

- fever
- fever and a rash
- fever with high heart rate
- headache with nausea or vomiting
- headache and fever
- headache with stiff neck or stiff back
- confusion
- eyes sensitive to light
- muscle aches with flu-like symptoms



Get emergency medical care right away if you have any of these signs and symptoms and show this card to any healthcare provider who treats you.


Your risk of meningococcal infection may continue for several months after your last dose of ULTOMIRIS or SOLIRIS.

For **ULTOMIRIS**, keep this card with you at all times during your treatment and for 8 months after your last dose.

For **SOLIRIS**, keep this card with you at all times during your treatment and for 3 months after your last dose.


PATIENT SAFETY CARD

Information for the Treating Healthcare Provider

 This patient has been prescribed **ULTOMIRIS (ravulizumab-cwvz) or SOLIRIS (eculizumab)** therapy, which increases the patient's susceptibility to meningococcal infections (*Neisseria meningitidis*) or other general infections.

- Meningococcal infections may become rapidly life-threatening or fatal if not recognized and treated early.
- **Closely monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected. Promptly treat known infections.**
- Contact the healthcare provider who prescribed ULTOMIRIS or SOLIRIS (listed below) as soon as possible if the patient has signs or symptoms of serious meningococcal infection.

For more information about ULTOMIRIS or SOLIRIS, please refer to the Prescribing Information. Report adverse events suggestive of serious meningococcal infections at **1-844-259-6783**.

 Patients receiving ULTOMIRIS or SOLIRIS should carry this card at all times. ULTOMIRIS patients should carry for 8 months after the last dose of treatment and SOLIRIS patients should carry for 3 months after the last dose of treatment. Show this card to any healthcare provider involved in your health care.

Patient Name _____

Prescriber Name _____

Prescriber Phone _____

Phone: 1-888-765-4747 www.UltSolREMS.com Fax: 1-866-750-0481



ULTOMIRIS, SOLIRIS, ALEXION, and the Alexion logo are registered trademarks of Alexion Pharmaceuticals, Inc. © 2024, Alexion Pharmaceuticals, Inc. All rights reserved. Approved 03/2024.